Engineering liver
Name
Griffith_Engineering liver.pdf
Size
688.25 KB
Format
Adobe PDF
Checksum (MD5)
a74f21a34c0ad2942928230e8933fe0b
Author(s)
Griffith, Linda G.
Wells, Alan
Stolz, Donna B.
Date Issued
May 2014
Journal
Hepatology
Publisher
Wiley Blackwell
Citation
Griffith, Linda G., Alan Wells, and Donna B. Stolz. “Engineering Liver.” Hepatology 60, no. 4 (May 19, 2014): 1426–1434.
Version
Author's final manuscript
Abstract
Interest in “engineering liver” arises from multiple communities: therapeutic replacement; mechanistic models of human processes; and drug safety and efficacy studies. An explosion of micro- and nanofabrication, biomaterials, microfluidic, and other technologies potentially affords unprecedented opportunity to create microphysiological models of the human liver, but engineering design principles for how to deploy these tools effectively toward specific applications, including how to define the essential constraints of any given application (available sources of cells, acceptable cost, and user-friendliness), are still emerging. Arguably less appreciated is the parallel growth in computational systems biology approaches toward these same problems—particularly in parsing complex disease processes from clinical material, building models of response networks, and in how to interpret the growing compendium of data on drug efficacy and toxicology in patient populations. Here, we provide insight into how the complementary paths of engineering liver—experimental and computational—are beginning to interplay toward greater illumination of human disease states and technologies for drug development.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/hep.27150
